Nadia Bouabdallaoui1, Brian Claggett2, Michael R Zile3, John J V McMurray4, Eileen O'Meara1, Milton Packer5, Margarett F Prescott6, Karl Swedberg7, Scott D Solomon2, Jean L Rouleau1. 1. Montreal Heart Institute and University of Montreal, Montreal, Quebec, Canada. 2. Brigham and Women's Hospital, Boston, MA, USA. 3. Medical University of South Carolina and Ralph H. Johnson Veterans Administration Medical Center, Charleston, SC, USA. 4. BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK. 5. Baylor University Medical Center, Dallas, TX, USA. 6. Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. 7. University of Gothenburg, Gothenburg, Sweden.
Abstract
AIMS: Growth differentiation factor-15 (GDF-15) is associated with adverse prognosis in cardiovascular (CV) and non-CV diseases. We evaluated the association of GDF-15 with CV and non-CV outcomes in the PARADIGM-HF trial. METHODS AND RESULTS: In 1935 patients with heart failure and reduced ejection fraction (HFrEF) in PARADIGM-HF, median GDF-15 values were elevated and similar in sacubitril/valsartan and enalapril patients (1626 ng/L and 1690 ng/L, respectively). Diabetes, age, creatinine, high-sensitive troponin T, N-terminal pro-B-type natriuretic peptide, and New York Heart Association class III/IV were most strongly associated with elevated GDF-15 values (all P < 0.001) (adjusted R2 = 0.3857). Baseline GDF-15 and changes in GDF-15 at both 1 month and 8 months (log-transformed) were associated with subsequent mortality and CV events. Each 20% increment in baseline GDF-15 value was associated with a higher risk of mortality [adjusted hazard ratio (HR) 1.13, 95% confidence interval (CI) 1.08-1.18, P < 0.001], the combined endpoint of CV death or hospitalization for heart failure (adjusted HR 1.09, 95% CI 1.05-1.14, P < 0.001) and heart failure death (adjusted HR 1.16, 95% CI 1.05-1.28, P < 0.001). Changes in GDF-15 were not influenced by assigned therapy (all P-values ≥ 0.1). CONCLUSION: In patients with ambulatory HFrEF, GDF-15 is not modified by sacubitril/valsartan and is strongly associated with mortality and CV outcomes, suggesting that GDF-15 is a marker of poor outcomes in these patients. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov Identifier NCT01035255.
RCT Entities:
AIMS: Growth differentiation factor-15 (GDF-15) is associated with adverse prognosis in cardiovascular (CV) and non-CV diseases. We evaluated the association of GDF-15 with CV and non-CV outcomes in the PARADIGM-HF trial. METHODS AND RESULTS: In 1935 patients with heart failure and reduced ejection fraction (HFrEF) in PARADIGM-HF, median GDF-15 values were elevated and similar in sacubitril/valsartan and enalaprilpatients (1626 ng/L and 1690 ng/L, respectively). Diabetes, age, creatinine, high-sensitive troponin T, N-terminal pro-B-type natriuretic peptide, and New York Heart Association class III/IV were most strongly associated with elevated GDF-15 values (all P < 0.001) (adjusted R2 = 0.3857). Baseline GDF-15 and changes in GDF-15 at both 1 month and 8 months (log-transformed) were associated with subsequent mortality and CV events. Each 20% increment in baseline GDF-15 value was associated with a higher risk of mortality [adjusted hazard ratio (HR) 1.13, 95% confidence interval (CI) 1.08-1.18, P < 0.001], the combined endpoint of CV death or hospitalization for heart failure (adjusted HR 1.09, 95% CI 1.05-1.14, P < 0.001) and heart failure death (adjusted HR 1.16, 95% CI 1.05-1.28, P < 0.001). Changes in GDF-15 were not influenced by assigned therapy (all P-values ≥ 0.1). CONCLUSION: In patients with ambulatory HFrEF, GDF-15 is not modified by sacubitril/valsartan and is strongly associated with mortality and CV outcomes, suggesting that GDF-15 is a marker of poor outcomes in these patients. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov Identifier NCT01035255.
Authors: Paul Welsh; Dorien M Kimenai; Riccardo E Marioni; Caroline Hayward; Archie Campbell; David Porteous; Nicholas L Mills; Stephen O'Rahilly; Naveed Sattar Journal: Clin Chem Lab Med Date: 2022-08-18 Impact factor: 8.490
Authors: Nathan R Stein; Leila R Zelnick; Amanda H Anderson; Robert H Christenson; Christopher R deFilippi; Rajat Deo; Alan S Go; Jiang He; Bonnie Ky; James P Lash; Stephen L Seliger; Elsayed Z Soliman; Michael G Shlipak; Nisha Bansal Journal: Kidney Int Rep Date: 2020-05-07
Authors: Patrícia Lourenço; Filipe M Cunha; João Ferreira-Coimbra; Isaac Barroso; João-Tiago Guimarães; Paulo Bettencourt Journal: ESC Heart Fail Date: 2021-05-02
Authors: João Pedro Ferreira; Kévin Duarte; Holger Woehrle; Martin R Cowie; Karl Wegscheider; Christiane Angermann; Marie-Pia d'Ortho; Erland Erdmann; Patrick Levy; Anita K Simonds; Virend K Somers; Helmut Teschler; Patrick Rossignol; Wolfgang Koenig; Faiez Zannad Journal: ESC Heart Fail Date: 2020-01-17